Le mois d'octobre marque le début d'un nouvel exercice financier pour l'USPTO. La semaine dernière, l'agence a annoncé la prolongation de plusieurs programmes pilotes qui se poursuivront jusqu'en 2023 et au-delà.
The Cancer Immunotherapy Pilot Program
The Cancer Immunotherapy Pilot Program (also referred to as the Patents 4 Patients program) has been extend through January 31, 2023. This program is intended to support the Cancer Moonshot initiative and promote innovation in cancer treatments by offering fee-free expedited examination of patent applications claiming methods of treating cancer using immunotherapy. In announcing the extension, the USPTO reported that so far over 650 patents have been granted under the pilot program.
Other subject-matter specific expedited examination programs include the Climate Change Mitigation Pilot Program (for innovations that reduce greenhouse gas emissions) set to expire June 5, 2023, and the Covid-19 Prioritized Examination Pilot Program (open only to applications with Small Entity or Micro Entity status) set to expire December 31, 2022.
The After Final Consideration Pilot Program 2.0
The After Final Consideration Pilot (AFCP) Program 2.0 has been extended to September 30, 2023. As explained on the USPTO’s AFCP 2.0 webpage, the program “authorizes additional time for examiners to search and/or consider responses after final rejection.” As noted in this article, AFCP 2.0 is intended to “reduc[e] the number of Requests for Continued Examination (RCE) and encourage[e] increased collaboration between the applicant and the examiner to effectively advance the prosecution of the application.”
Since the program was rolled out in May 2013, many stakeholders wonder how it is still a “pilot” program, and whether it has been successful.
The Fast-Track (Ex Parte) Appeals Pilot Program
The Fast-Track Appeals Pilot Program has been extended through July 2, 2024. As explained in this article, this program offers applicants an opportunity to expedite Board review of ex parte appeals of an examiner’s rejection, for a fee of $400. In announcing the extension, the USPTO reported that “the current average appeal pendency is about 12 months, down from 15 months in 2020, and 30 months in 2015.” The announcement seems to encourage applicants to consider appealing final rejections instead of continuing prosecution, stating that “[u]sing the appeal process may be more expeditious for inventors and may speed the ultimate issuance of patents as opposed to request for continued examination practice.”
